MESOM
MCID: MST016
MIFTS: 51

Mesothelioma, Somatic (MESOM) malady

Categories: Genetic diseases, Rare diseases, Respiratory diseases, Cancer diseases

Aliases & Classifications for Mesothelioma, Somatic

Aliases & Descriptions for Mesothelioma, Somatic:

Name: Mesothelioma, Somatic 54 13
Malignant Mesothelioma 12 50 29 52 14 69
Mesothelioma, Malignant 54 50 66 42
Advanced Malignant Mesothelioma 12 69
Pleural Mesothelioma 56 69
Asbestos-Related Malignant Mesothelioma 12
Diffuse Malignant Mesothelioma 12
Malignant Tumor of Mesothelium 12
Malignant Pleural Mesothelioma 69
Mesothelioma Diffuse Malignant 52
Mesothelioma 69
Mesom 66

Characteristics:

Orphanet epidemiological data:

56
pleural mesothelioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare respiratory diseases


External Ids:

OMIM 54 156240
Disease Ontology 12 DOID:1790
SNOMED-CT 64 62064005
Orphanet 56 ORPHA50251
UMLS via Orphanet 70 C0025500
MESH via Orphanet 43 D008654
ICD10 via Orphanet 34 C45.0
MedGen 40 C0345967

Summaries for Mesothelioma, Somatic

NIH Rare Diseases : 50 malignant mesothelioma is a form of cancer that develops in the thin layer of tissue that surrounds the lungs, chest wall, or abdomen. signs and symptoms of the condition can vary and often depend on which area of the body is affected. common features include abdominal bloating, abdominal pain, chest pain, coughing, fatigue, shortness of breath, and/or weight loss. malignant mesothelioma is thought to be caused by long-term exposure to asbestos (a fire-resistant material that was once commonly found in insulation; ceiling and roof vinyls; cement; and automotive brake materials). most people appear to be diagnosed with the condition approximately 30 years after being in contact with the asbestos. unfortunately, there is generally no cure for malignant mesothelioma unless it is diagnosed at an early stage and can be surgically removed. if surgery is not an option, chemotherapy and/or radiation therapy may still be recommended to help alleviate some of the associated symptoms. last updated: 11/12/2015

MalaCards based summary : Mesothelioma, Somatic, also known as malignant mesothelioma, is related to ovarian malignant mesothelioma and malignant pleural mesothelioma, and has symptoms including malignant mesothelioma, chest pain and dyspnea. An important gene associated with Mesothelioma, Somatic is BCL10 (B-Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Cytoskeletal Signaling and Bladder cancer. The drugs Alimta and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include lung, and related phenotypes are cardiovascular system and cellular

Disease Ontology : 12 A cell type cancer that has material basis in mesothelial tissue.

OMIM : 54 Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos.... (156240) more...

UniProtKB/Swiss-Prot : 66 Mesothelioma, malignant: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.

Related Diseases for Mesothelioma, Somatic

Diseases related to Mesothelioma, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
id Related Disease Score Top Affiliating Genes
1 ovarian malignant mesothelioma 11.9
2 malignant pleural mesothelioma 11.4
3 peritoneal mesothelioma 11.4
4 malignant peritoneal mesothelioma 11.3
5 pericardial mesothelioma 11.2
6 malignant epithelial mesothelioma 11.1
7 malignant biphasic mesothelioma 10.8
8 sarcomatoid mesothelioma 10.8
9 testicular malignant germ cell cancer 10.4 CDKN2A WT1
10 immunodeficiency due to a classical component pathway complement deficiency 10.3 CDKN2A MUC1 NF2
11 porokeratosis 10.3 MUC1 NF2 NKX2-1
12 perivascular epithelioid cell tumor 10.3 KRT20 THBD WT1
13 thymus lipoma 10.3 CALB2 WT1
14 ovary mixed epithelial carcinoma 10.3 CDH1 NF2
15 cyanide-induced parkinsonism 10.3 CALB2 CDH1
16 meninges hemangiopericytoma 10.3 CDKN2A KRT20 WT1
17 gestational trophoblastic neoplasm 10.3 CALB2 MUC1 WT1
18 pacinian tumor 10.3 CDKN2A KRT20 NKX2-1
19 pathologic nystagmus 10.3 CDKN2A MUC1 NF2
20 sagittal sinus thrombosis 10.3 CDH2 KRT20 MUC1
21 diabetes persistent mullerian ducts 10.3 MUC1 THBD WT1
22 embryonal testis carcinoma 10.3 CDH1 KRT20 MUC1
23 placental site trophoblastic tumor 10.3 CDKN2A KRT20 MUC1
24 monckeberg arteriosclerosis 10.3 CDKN2A NF2 PDPN
25 gallbladder signet ring cell adenocarcinoma 10.3 CDH1 KRT20 MUC1
26 bronchogenic lung adenocarcinoma 10.3 CEACAM5 MUC1
27 hunter macpherson syndrome 10.3 CALB2 KRT20 NKX2-1
28 fallopian tube leiomyosarcoma 10.3 CDH1 CDKN2A MUC1
29 ovarian insufficiency due to fsh resistance 10.2 MET MUC1 SPP1
30 petrous apex meningioma 10.2 CALB2 MUC1 THBD WT1
31 brown-vialetto-van laere syndrome 10.2 KRT20 MUC1 NKX2-1 WT1
32 allergic contact dermatitis 10.2 CDKN2A KRT20 MUC1 NKX2-1
33 meige syndrome 10.2 KRT20 MUC1 NKX2-1
34 thymic dysplasia 10.2 CALB2 MUC1
35 traumatic brain injury 10.2 CDH1 CDH2 CDKN2A
36 lacrimal gland mucoepidermoid carcinoma 10.2 CEACAM5 MUC1
37 mesenteric vascular occlusion 10.2 CALB2 PDPN WT1
38 hyperandrogenism 10.2 CALB2 MSLN THBD
39 ovarian endometrioid cystadenofibroma 10.2 CALB2 CEACAM5 THBD
40 progesterone-receptor positive breast cancer 10.2 CDH1 CDKN2A MUC1
41 avian influenza 10.2 CDKN2A MUC1 NKX2-1 THBD WT1
42 vulva squamous cell carcinoma 10.2 CDKN2A CEACAM5 KRT20
43 myotonia congenita 10.2 CDKN2A CEACAM5 KRT20
44 estrogen-receptor positive breast cancer 10.2 CDH1 CDKN2A PDPN
45 bronchitis 10.2 CDH1 NF2
46 gastroesophageal junction adenocarcinoma 10.2 CDH1 CDH2 KRT20 MUC1
47 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 CDH1 CDKN2A RASSF1
48 papillary adenofibroma 10.2 CEACAM5 KRT20 MUC1
49 sengers syndrome 10.2 CDH1 CDKN2A MET MUC1
50 prostate stromal sarcoma 10.2 CEACAM5 KRT20 THBD

Graphical network of the top 20 diseases related to Mesothelioma, Somatic:



Diseases related to Mesothelioma, Somatic

Symptoms & Phenotypes for Mesothelioma, Somatic

Symptoms by clinical synopsis from OMIM:

156240

Clinical features from OMIM:

156240

Human phenotypes related to Mesothelioma, Somatic:

32
id Description HPO Frequency HPO Source Accession
1 malignant mesothelioma 32 HP:0100001

UMLS symptoms related to Mesothelioma, Somatic:


chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Mesothelioma, Somatic:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 CDH1 CDH2 CDKN2A MET NKX2-1 PDPN
2 cellular MP:0005384 10.24 BCL10 CDH1 CDH2 CDKN2A MCL1 MET
3 homeostasis/metabolism MP:0005376 10.18 WT1 SPP1 THBD TNFSF10 CDH1 CDH2
4 immune system MP:0005387 10.15 MET NF2 PDPN RASSF1 SPP1 THBD
5 endocrine/exocrine gland MP:0005379 10.13 BCL10 CDH1 CDKN2A MCL1 MET NF2
6 embryo MP:0005380 10.11 BCL10 CDH1 CDH2 CDKN2A MCL1 MET
7 mortality/aging MP:0010768 10.1 SPP1 THBD TNFSF10 WT1 BCL10 CDH1
8 digestive/alimentary MP:0005381 10.02 CDH1 CDKN2A MET NKX2-1 PDPN RASSF1
9 liver/biliary system MP:0005370 9.92 CDKN2A MET NF2 RASSF1 SPP1 THBD
10 neoplasm MP:0002006 9.81 CDH1 CDKN2A MET NF2 NKX2-1 RASSF1
11 normal MP:0002873 9.61 CALB2 CDH1 MCL1 MET MSLN NKX2-1
12 respiratory system MP:0005388 9.23 WT1 CDKN2A MET NF2 NKX2-1 PDPN

Drugs & Therapeutics for Mesothelioma, Somatic

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Alimta 17 46 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004

Drugs for Mesothelioma, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 288)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
4
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
5
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 5460373 44475014
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
7
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
8
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
Raltitrexed Approved, Investigational Phase 3,Phase 2,Phase 1 112887-68-0 104758
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
12
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
13
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
18
Nintedanib Approved Phase 3,Phase 2,Phase 1 656247-17-5 56843413
19
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
22
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
23
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
24 Ranpirnase Investigational Phase 3 196488-72-9
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Antimetabolites Phase 3,Phase 2,Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
30 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
31 Vitamin B Complex Phase 3,Phase 2,Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
36 Mitomycins Phase 3,Phase 2
37 Vitamin B 12 Phase 2, Phase 3
38 Vitamins Phase 2, Phase 3, Phase 1
39 Antiemetics Phase 3,Phase 2,Phase 1
40 Autonomic Agents Phase 3,Phase 2,Phase 1
41 BB 1101 Phase 3,Phase 2,Phase 1
42 Dexamethasone 21-phosphate Phase 3,Phase 2,Phase 1
43 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
44 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
45 Micronutrients Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
47 Trace Elements Phase 3,Phase 2,Phase 1
48 Analgesics Phase 3,Phase 1,Phase 2
49 Liver Extracts Phase 3,Phase 2,Phase 1
50 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 347)
id Name Status NCT ID Phase
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3
2 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3
3 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3
4 Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma Completed NCT00006231 Phase 3
5 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
6 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3
7 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3
8 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3
9 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3
10 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
12 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
13 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
14 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Recruiting NCT01604005 Phase 3
15 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma Recruiting NCT03063450 Phase 3
16 Nintedanib (BIBF 1120) in Mesothelioma Recruiting NCT01907100 Phase 3
17 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Recruiting NCT02899299 Phase 3
18 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3
19 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Active, not recruiting NCT01098266 Phase 3
20 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
21 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies Active, not recruiting NCT01401907 Phase 3
22 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Not yet recruiting NCT02991482 Phase 3
23 Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication Withdrawn NCT02511600 Phase 3
24 An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Unknown status NCT00685204 Phase 2
25 Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma Unknown status NCT00030459 Phase 2
26 The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma Unknown status NCT01655888 Phase 2
27 A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Unknown status NCT01649024 Phase 2
28 Sorafenib in Previously Treated Malignant Mesothelioma Unknown status NCT00794859 Phase 2
29 A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma Unknown status NCT00551252 Phase 2
30 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2
31 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2
32 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2
33 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2
34 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2
35 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2
36 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2
37 High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2
38 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2
39 Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma Unknown status NCT01281800 Phase 2
40 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
41 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2
42 Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis Unknown status NCT00454519 Phase 2
43 ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. Approved for marketing NCT00040625 Phase 2
44 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Completed NCT00509041 Phase 2
45 SU5416 in Treating Patients With Malignant Mesothelioma Completed NCT00006014 Phase 2
46 Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed Completed NCT00004254 Phase 2
47 An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma Completed NCT00787410 Phase 2
48 Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma Completed NCT00458913 Phase 2
49 S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery Completed NCT00003723 Phase 2
50 PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Completed NCT00053885 Phase 2

Search NIH Clinical Center for Mesothelioma, Somatic

Cochrane evidence based reviews: mesothelioma, malignant

Genetic Tests for Mesothelioma, Somatic

Genetic tests related to Mesothelioma, Somatic:

id Genetic test Affiliating Genes
1 Mesothelioma, Malignant 29

Anatomical Context for Mesothelioma, Somatic

MalaCards organs/tissues related to Mesothelioma, Somatic:

39
Lung

Publications for Mesothelioma, Somatic

Variations for Mesothelioma, Somatic

ClinVar genetic disease variations for Mesothelioma, Somatic:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 WT1 NM_024426.4(WT1): c.1021A> G (p.Ser341Gly) single nucleotide variant Pathogenic rs121907908 GRCh37 Chromosome 11, 32421571: 32421571
2 BCL10 NM_003921.4(BCL10): c.499dupT (p.Ser167Phefs) duplication Pathogenic rs387906350 GRCh37 Chromosome 1, 85733513: 85733513
3 BCL10 NM_003921.4(BCL10): c.136delA (p.Ile46Tyrfs) deletion Pathogenic rs587776639 GRCh37 Chromosome 1, 85736511: 85736511

Copy number variations for Mesothelioma, Somatic from CNVD:

7 (show all 35)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13405 1 1 2300000 Loss Malignant mesothelioma
2 21838 1 16200000 28000000 Loss Malignant mesothelioma
3 33950 1 50700000 61300000 Amplification Malignant mesothelioma
4 35952 1 69700000 116100000 Loss Malignant mesothelioma
5 35954 1 69700000 116100000 Loss CLCA1 Malignant mesothelioma
6 35956 1 69700000 116100000 Loss CLCA2 Malignant mesothelioma
7 35958 1 69700000 116100000 Loss CLCA3 Malignant mesothelioma
8 35960 1 69700000 116100000 Loss CLCA4 Malignant mesothelioma
9 35962 1 69700000 116100000 Loss COL11A1 Malignant mesothelioma
10 35964 1 69700000 116100000 Loss TGFBR3 Malignant mesothelioma
11 35966 1 69700000 120600000 Loss Malignant mesothelioma
12 37056 1 84900000 107200000 Loss Malignant mesothelioma
13 69952 12 56600000 58100000 Gain Malignant mesothelioma
14 75172 13 17900000 45800000 Loss BRCA2 Malignant mesothelioma
15 85738 14 50900000 107349540 Loss CCNK Malignant mesothelioma
16 85740 14 50900000 107349540 Loss CDKN3 Malignant mesothelioma
17 113645 17 44900000 81195210 Gain ERN1 Malignant mesothelioma
18 113647 17 44900000 81195210 Gain MAP3K3 Malignant mesothelioma
19 113649 17 44900000 81195210 Gain PRKCA Malignant mesothelioma
20 113651 17 44900000 81195210 Gain SMARCD2 Malignant mesothelioma
21 175422 3 39400000 63700000 Loss CACNA2D3 Malignant mesothelioma
22 175424 3 39400000 63700000 Loss CTNNB1 Malignant mesothelioma
23 175426 3 39400000 63700000 Loss MLH1 Malignant mesothelioma
24 175771 3 44100000 44200000 Loss Malignant mesothelioma
25 187512 4 50400000 191154276 Loss Malignant mesothelioma
26 191705 5 1 48400000 Gain Malignant mesothelioma
27 204729 6 114600000 118300000 Loss HDAC2 Malignant mesothelioma
28 204731 6 114600000 118300000 Loss MARCKS Malignant mesothelioma
29 217075 7 1 4500000 Gain Malignant mesothelioma
30 234871 8 139900000 146364022 Gain Malignant mesothelioma
31 250026 9 19900000 25600000 Loss C9orf14 Malignant mesothelioma
32 250029 9 19900000 25600000 Loss CDKN2A Malignant mesothelioma
33 250031 9 19900000 25600000 Loss CDKN2B Malignant mesothelioma
34 250069 9 19900000 33200000 Loss Malignant mesothelioma
35 251883 9 33200000 36300000 Gain Malignant mesothelioma

Expression for Mesothelioma, Somatic

Search GEO for disease gene expression data for Mesothelioma, Somatic.

Pathways for Mesothelioma, Somatic

Pathways related to Mesothelioma, Somatic according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.04 CDH1 KRT20 MUC1 NF2 PDPN
2 11.41 CDH1 CDKN2A RASSF1
3 11.21 CDKN2A MCL1 TNFSF10
4 11.06 CDH1 CDH2 CEACAM5 MSLN MUC1
5 11.03 CDH1 CDH2 MET
6 10.93 CDH1 CDH2 MET SPP1

GO Terms for Mesothelioma, Somatic

Cellular components related to Mesothelioma, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 9.26 CDH1 CDH2 NF2 PDPN
2 catenin complex GO:0016342 9.16 CDH1 CDH2
3 cortical actin cytoskeleton GO:0030864 8.8 CDH1 CDH2 NF2

Biological processes related to Mesothelioma, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of anoikis GO:2000811 9.32 CEACAM5 MCL1
2 negative regulation of cell-matrix adhesion GO:0001953 9.26 CDKN2A NF2
3 negative regulation of cell-cell adhesion GO:0022408 9.16 CDH1 NF2
4 positive regulation of transcription, DNA-templated GO:0045893 9.1 BCL10 CDH1 CDKN2A NKX2-1 SPP1 WT1
5 entry of bacterium into host cell GO:0035635 8.96 CDH1 MET

Molecular functions related to Mesothelioma, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 BCL10 CDH1 CDH2 CDKN2A KRT20 MCL1
2 gamma-catenin binding GO:0045295 8.96 CDH1 CDH2

Sources for Mesothelioma, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....